Clinical Trial Update: Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer [Phase 2]

View source ↗

Summary

This trial update notes the completion of a Phase 2 study evaluating PTK787 for non-metastatic androgen-independent prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PTK787 (Vatalanib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED